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OBJECTIVES: The department of Dermatology of the
University hospital Maastricht performed a randomised
trial to compare the cost-effectiveness of surgical excision
(SE) and Mohs Micrographic surgery (MMS) in a group
of patients with primary and recurrent facial Basal Cell
Carcinoma (BCC). METHODS: Hospital costs, recur-
rence rates and quality of life data (NHP and STAI) were
collected during a time period of 18 months. The Incre-
mental Cost Effectiveness Ratio’s were calculated based
on incremental costs per recurrence avoided, both for
primary and recurrent BCC. The reliability of the ICER
was estimated by means of bootstrap simulations.
RESULTS: In total 408 primary BCC and 204 recurrent
BCC were randomised to either SE or MMS. The ICER
for primary BCC amounted to €25.200. Seventy-four
percent of all ratio’s were within the quadrant where
MMS is more effective but also more costly. Twenty-four
percent of all ratio’s were in the quadrant where SE dom-
inates. The ICER for recurrent BCC amounted to €7.733.
All ratios were within the quadrant where MMS is more
effective but also more costly. For both primary and
recurrent BCC group, quality of life was not statistically
signiﬁcant different between SE and MMS. CONCLU-
SIONS: Based on costs and the recurrence rates, it is not
cost-effective to introduce MMS for primary BCC on a
large scale. However, other aspects like the patient per-
spective have not been examined in this study. It is pos-
sible that patients have a speciﬁc preference for either one
of the two treatment modalities. For the recurrent BCC
both ICER and bootstrap results should be treated with
caution since only ﬁfty percent of the patients with recur-
rent BCC have completed their 18-month follow-up. 
Possible changes in the recurrence rate may have a con-
siderable effect on the ﬁnal cost-effectiveness ratio of this
group.
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OBJECTIVES: To evaluate cost implications of oral
chemotherapy with capecitabine vs. standard ﬂuoropy-
rimidine-therapies (Mayo Clinic and AIO/Ardalan-
regimen), in different treatment settings in Germany.
METHODS: Costs of ﬂuoropyrimidine-therapies were
evaluated for the ofﬁce-based setting. Physician’s fees (89
quarterly fee-listings, 26 patients, 6 ofﬁce-based oncolo-
gists), drug and pharmacy costs and costs for venous 
port systems and single-use pumps were included.
Capecitabine treatment costs were assumed to be identi-
cal to the cost of the Mayo Clinic-regimen, except drug
administration and acquisition. Based on the frequency
of administration of active drugs by ofﬁce-based oncolo-
gists costs were modelled for 4 scenarios in the hospital
sector, i.e. in- and outpatient treatment in university- and
municipal hospitals. A third-party payer perspective was
adopted. Market research data on frequency and setting
of use of the evaluated regimens were used to estimate
potential overall cost implications. RESULTS: Treatment
costs for a 6-months course in the ofﬁce-based setting was
most expensive with the AIO/Ardalan regimen (€20,358)
and cheapest with capecitabine (€4776). In contrast, 
the AIO/Ardalan-protocol was cheaper than the Mayo
Clinic-protocol in all hospital settings (AIO/Ardalan
€2588–13,434; Mayo Clinic 4072–21,138). Potential
direct yearly savings by switching patients from Mayo-
Clinic- or AIO/Ardalan-regimen to oral capecitabine were
estimated at €78–84 Mio. CONCLUSION: The most
expensive treatment options were the AIO/Ardalan-pro-
tocol in the ofﬁce-based setting and the Mayo Clinic pro-
tocol in the hospital setting. Interestingly, remuneration
for hospitals is unlikely to be cost covering for some treat-
ment situations, in particular with the AIO/Ardalan-
regimen. Capecitabine emerged as the cheapest option 
in the ofﬁce-based setting (NA for hospital due to 
oral administration). Transferring patients to oral
capecitabine is likely to result in substantial cost savings,
estimated at €78–84 Mio annually. Savings are likely to
be substantially higher if combination therapies with
irinotecan or oxaliplatin are considered.
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OBJECTIVE: Gastric cancer is the most frequent cancer
in Japan and is an important cause of growing national
Health care costs. However, few studies focusing on the
costs of treating gastric cancer in Japan have been con-
ducted. We previously reported the costs of chemother-
apy for advanced or recurrent gastric cancer. Our results
have shown that the costs of hospitalization and sup-
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portive care were cost-drivers in total medical costs
during chemotherapy. In this study, we comprehensively
investigated medical costs from diagnosis through termi-
nal care in patients with advanced or recurrent gastric
cancer. METHODS: Patients with advanced or recurrent
gastric cancer who received the newly developed oral 
ﬂuoropyrimidine TS-1 or conventional intravenous
chemotherapy were identiﬁed on the basis of ordering
system data at Showa University Hospital from January
1998 through July 2001. The costs during diagnosis,
chemotherapy, and terminal care were evaluated accord-
ing to Japanese National Health Insurance fee schedule.
RESULTS: Costs were evaluated in 13 patients receiving
TS-1 and in 10 patients receiving conventional intra-
venous chemotherapy. Monthly costs during diagnosis,
chemotherapy, and terminal care in the TS-1 group were
597,057 +/- /105,148 (mean +/- SE) Yen, 327,640 
+/1 47,647 Yen, and 687,595 +/- /96,276 Yen. The 
corresponding costs for conventional intravenous
chemotherapy were 615,150 +/1/95,299 Yen, 852,874
+/-/ 62,412 Yen, and 619,721 +/-/ 86,745 Yen. Monthly
costs during chemotherapy were signiﬁcantly lower in 
the TS-1 group than in the conventional intravenous
chemotherapy group, whereas costs during diagnosis and
terminal care were similar in the groups. CONCLU-
SIONS: Medical costs from diagnosis through terminal
care are high in patients with advanced or recurrent
gastric cancer. The use of oral anticancer drugs such as
TS-1, which facilitates transition from inpatient to ambu-
latory treatment, reduces medical costs in patients with
gastric cancer.
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Data on head and neck cancer (HNSCC) is lacking, espe-
cially in France. OBJECTIVES: Estimate the costs of
inoperable HNSCC patients treated in the private sector
and their relationship with patient’s medical characteris-
tics. METHODS: We conducted a cohort study in one
centre to collect medical data from diagnosis until date
of last news or death. Reimbursements of medical fees
were obtained from the French Sickness Fund. For the
private sector, fee for service rules are applied; as a con-
sequence, all types of health care consumptions could be
identiﬁed. Consumptions were further linked to treatment
phases (initial treatment, follow-up, palliative care) and
medical events (chemotherapy, radiotherapy, relapse,
adverse event . . .). Logistic regression was carried out to
identify which of the medical characteristics (perfor-
mance, status, staging, age, localisation) were the main
cost drivers. Thirty patients were included and mean
duration of follow-up was 13.8 months. Mean total direct
costs was estimated at €20,752 per patient, with more
than one half for initial radio-chemotherapy (€11,399)
phase, around one quarter for follow-up (€4684) and the
same for palliative care (€4669). 14 patients died during
the study and only 9 received palliative care for an
average cost per treated patient of €15,563. RESULTS:
Type of care distribution varied according to treatment
phases with more hospitalisations and medical proce-
dures during initial treatment, more medication during
follow-up and more hospitalisation costs during pallia-
tive care. Costs of side effects were very high, particu-
larly those associated with mucositis that concerned all
patients with a mean cost of €4582 of which €1607 for
hospitalisation. CONCLUSIONS: Logistic regression
highlighted the importance of the nodal staging on the
mean total cost per patients and on the daily cost: €35
for AJCC stage III, €55 for stage IVa, €93 for stage IVb
patients.
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OBJECTIVES: The prognosis of non-small cell lung
cancer (NSCLC) patients is determined by mediastinal
lymph node involvement at the time of diagnosis. The
objective of this study was to investigate the cost conse-
quences of using endoscopic ultrasonography with ﬁne-
needle aspiration (EUS-FNA) instead of mediastinoscopy
(MS) or explorative thoracotomy (ET) in patients with
NSCLC and suspected mediastinal involvement on
positron emission tomography (PET). METHODS:
Potentially operable patients with NSCLC and positive
PET were eligible. If EUS-FNA was negative or inconclu-
sive, patients underwent MS. If MS was negative, ET was
performed. If EUS-FNA was positive for malignancy, no
ET was performed. The primary outcome was the reduc-
tion of invasive diagnostic procedures and as a result, the
reduction of direct medical costs, assessed from the hos-
pital viewpoint. The time horizon was the diagnostic tra-
jectory until discharge from the hospital. RESULTS:
Of 82 patients, 49 (60%) had positive EUS-FNA, and 
did not undergo invasive diagnostic procedures. In 33
patients (40%) EUS-FNA was either negative (6) or
inconclusive (27). Surgical staging by MS or ET was per-
formed in 26 of these 33 patients: 12 patients underwent
MS, nine patients had ET, and four patients both proce-
dures. The costs were $1590 for MS and $5822 for ET.
The costs for EUS-FNA were $591. Assuming that,
without EUS-FNA, all patients would undergo MS, and
15% would need additional ET to reach a diagnosis, the
differences in total costs were calculated at $55,000.
CONCLUSIONS: Introduction of EUS-FNA in the diag-
